/
/
/

Tatva Chintan Pharma Chem Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020
₹167 Cr₹134 Cr₹131 Cr₹124 Cr₹117 Cr₹108 Cr₹86 Cr₹83 Cr₹105 Cr₹98 Cr₹84 Cr₹97 Cr₹114 Cr₹125 Cr₹121 Cr₹90 Cr₹88 Cr₹99 Cr₹105 Cr₹124 Cr₹107 Cr₹109 Cr₹80 Cr₹60 Cr₹52 Cr
₹3 Cr-₹35 L₹2 Cr₹1 Cr₹1 Cr₹72 L₹4 L₹38 L₹1 Cr₹5 Cr₹1 Cr₹76 L₹1 Cr₹85 L₹1 Cr₹2 Cr₹2 Cr₹31 L₹5 Cr₹3 Cr₹3 Cr₹3 Cr₹66 L₹2 Cr₹17 L
₹170 Cr₹134 Cr₹133 Cr₹125 Cr₹118 Cr₹109 Cr₹86 Cr₹84 Cr₹107 Cr₹103 Cr₹85 Cr₹97 Cr₹115 Cr₹125 Cr₹122 Cr₹92 Cr₹90 Cr₹99 Cr₹109 Cr₹127 Cr₹110 Cr₹111 Cr₹81 Cr₹62 Cr₹52 Cr
₹145 Cr₹116 Cr₹115 Cr₹110 Cr₹109 Cr₹106 Cr₹86 Cr₹85 Cr₹100 Cr₹89 Cr₹80 Cr₹83 Cr₹99 Cr₹111 Cr₹105 Cr₹81 Cr₹76 Cr₹79 Cr₹83 Cr₹90 Cr₹83 Cr₹86 Cr₹57 Cr₹55 Cr₹43 Cr
₹35 Cr₹28 Cr₹27 Cr₹23 Cr₹18 Cr₹10 Cr₹7 Cr₹6 Cr₹14 Cr₹20 Cr₹12 Cr₹21 Cr₹22 Cr₹17 Cr₹19 Cr₹13 Cr₹17 Cr₹22 Cr₹29 Cr₹39 Cr₹29 Cr₹27 Cr₹25 Cr₹8 Cr₹11 Cr
₹2 Cr₹1 Cr₹49 L₹51 L₹41 L₹39 L₹42 L₹17 L₹31 L₹21 L₹38 L₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹1 Cr₹1 Cr₹99 L₹1 Cr₹3 Cr₹1 Cr₹1 Cr₹99 L₹50 L
₹21 Cr₹17 Cr₹18 Cr₹14 Cr₹9 Cr₹2 Cr-₹24 L-₹1 Cr₹7 Cr₹14 Cr₹5 Cr₹11 Cr₹13 Cr₹8 Cr₹14 Cr₹9 Cr₹14 Cr₹19 Cr₹25 Cr₹35 Cr₹24 Cr₹24 Cr₹22 Cr₹6 Cr₹8 Cr
₹16 Cr₹10 Cr₹15 Cr₹10 Cr₹7 Cr₹1 Cr₹14 L-₹66 L₹5 Cr₹10 Cr₹3 Cr₹8 Cr₹10 Cr₹17 Cr₹12 Cr₹7 Cr₹10 Cr₹18 Cr₹23 Cr₹32 Cr₹23 Cr₹21 Cr₹21 Cr₹4 Cr₹7 Cr

Share Price Live Stats

Open (₹)1,609.90
Volume (₹)25,475.00
High (₹)1,636.30
Upper Circuit1,915.40
Low (₹)1,580.10
Lower Circuit1,277.00
Prev Close1,596.20
52W High (₹)1,838.10
Price1,630.00
52W Low (₹)976.40

Share Market Cap & Key Ratios Overview

M.Cap (₹)3740.39 Cr
Div. Yield (%)0.13
PE Ratio72.79
Debt to Equity0.15
Price to Book3.14
Book Value334.20
EPS (TTM)21.97
Face Value10.00
ROE (%)5.53

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SOLARINDSNSE
PIDILITINDNSE
SRFNSE
FLUOROCHEMNSE
NAVINFLUORNSE
GODREJINDNSE
DEEPAKNTRNSE
AETHERNSE
ATULNSE
AARTIINDNSE
TATVANSE
LTP
1W Low
1W High
Market cap (₹)
21510+1110 (5.44%)
19810
21695
1,93,746Cr
1628.7-0.8 (-0.05%)
1612.40
1687.70
1,66,118Cr
2566.9-23 (-0.89%)
2532.20
2648
77,219Cr
4596.8-174.4 (-3.66%)
4550
4850
51,537Cr
8656+138.5 (1.63%)
8275.50
8740
44,624Cr
1169.4+1.9 (0.16%)
1128.50
1215.90
38,937Cr
1726-36.9 (-2.09%)
1705.70
1820
23,559Cr
1642.3-54.5 (-3.21%)
1626.60
1707.80
21,984Cr
6408-51.5 (-0.80%)
6358
6642.50
19,036Cr
501.2-39.15 (-7.25%)
496.10
540.60
18,200Cr
1630+0 (0.00%)
1563.60
1650
3,740Cr

Key Highlights of Tatva Chintan Pharma Chem Ltd’s P&L

In 2025-03-31, Tatva Chintan Pharma Chem Ltd reported total revenue of ₹385.03Cr, compared with ₹401.01Cr in 2024-03-31, reflecting Tatva Chintan Pharma Chem Ltd turnover.

Depreciation was ₹27.66Cr and finance costs were ₹1.51Cr in 2025-03-31

Profit Before Tax (PBT) has been ₹7.58Cr in 2025-03-31 as compared to ₹43.57Cr in 2024-03-31.

Net Profit (PAT) was ₹5.71Cr in 2025-03-31 compared with ₹30.35Cr in 2024-03-31.

Earnings per share (EPS) were ₹2.44 in 2025-03-31, compared with ₹12.98 in 2024-03-31.